Ann Dermatol.  2018 Aug;30(4):441-450. 10.5021/ad.2018.30.4.441.

An Open Label, Multi-Center, Non-Interventional Post-Marketing Surveillance to Monitor the Safety and Efficacy of ALTARGO® (Retapamulin) Administered in Korean Patients According to the Prescribing Information

• Hong W
• Lee YS
• Park CW
• Yoon MS
• Ro YS

• KMID: 2457521
• DOI: http://doi.org/10.5021/ad.2018.30.4.441

Abstract

BACKGROUND
With the approval of topical retapamulin ointment in 2011, it was officially required to conduct a post-marketing surveillance (PMS) study to obtain further data of its safety profile and effectiveness, in accordance with the requirement of the Korean Ministry of Food and Drug Safety (MFDS).
OBJECTIVE
This study had prospectively designed to monitor safety and tolerability with the effectiveness of topical retapamulin in clinical practices.
METHODS
Open label, multi-center, non-interventional observational study was done from May 2011 to October 2015. All subjects had bacterial skin infections of locally approved prescribing information accordingly. The study mainly focused on safety issues in the local target population (3,612 eligible subjects). And, drug effectiveness was also evaluated by physicians.
RESULTS
The incidence of adverse events (AEs) and adverse drug reactions (ADRs) were 2.53% and 0.97%, respectively. In terms of the incidence of unexpected AEs and ADRs, 1.45% and 0.33%, and for the incidence of serious AEs, 0.28%, whereas no serious ADRs reported. And, the effectiveness of topical retapamulin rate was 96.1% (1,697 of total 1,765 subjects).
CONCLUSION
Topical retapamulin is to be well-tolerated and effective in patients with bacterial skin infections of locally approved prescribing information.

Keyword

Anti-bacterial agents; Product surveillance; postmarketing; Skin diseases; infection

MeSH Terms

Anti-Bacterial Agents
Drug-Related Side Effects and Adverse Reactions
Health Services Needs and Demand
Humans
Incidence
Observational Study
Prospective Studies
Skin
Skin Diseases
Anti-Bacterial Agents

Reference

1. Champney WS, Rodgers WK. Retapamulin inhibition of translation and 50S ribosomal subunit formation in staphylococcus aureus cells. Antimicrob Agents Chemother. 2007; 51:3385–3387. PMID: 17562806.

2. Wolf R, Davidovici BB, Parish JL, Parish LC. Emergency dermatology. Cambridge, USA: Cambridge University Press;2011. p. 376.

3. Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother. 2006; 50:2583–2586. PMID: 16801451.

4. Korea Institute of Drug Safety & Risk Management. WHO-ART 092 [Internet]. Anyang: Korea Institute of Drug Safety & Risk Management;2015. 7. cited 2018 Jun 8. Available from: https://www.drugsafe.or.kr/iwt/ds/ko/bbs/EgovBbs.do;jsessionid=JcVbUVsrD2anWzye6BgkPqwiw4cktqW0oiFbNuq2WQaDVhqlgoXgLidzeTEGPuTz.webint_2_servlet_engine1?bbsId=BBSMSTR_000000000024&nttId=1446&pageIndex=2&searchCnd=&searchWrd=.

5. Kirst HA. Developing new antibacterials through natural product research. Expert Opin Drug Discov. 2013; 8:479–493. PMID: 23480029.

6. Yang LP, Keam SJ. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008; 68:855–873. PMID: 18416589.

7. Tang YZ, Liu YH, Chen JX. Pleuromutilin and its derivatives-the lead compounds for novel antibiotics. Mini Rev Med Chem. 2012; 12:53–61. PMID: 22070694.

8. Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D. Microbiological profile of a new topical antibacterial: retapamulin ointment 1%. Expert Rev Anti Infect Ther. 2009; 7:269–279. PMID: 19344241.

9. Jacobs MR. Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children. Future Microbial. 2007; 2:591–600.

10. Parish LC, Parish JL. Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections. Drugs Today (Barc). 2008; 44:91–102.

11. Physician's desk reference 2009. 63rd ed. Montvale: Thomson PDR;2008.

12. Novak R. Are pleuromutilin antibiotics finally fit for human use? Ann N Y Acad Sci. 2011; 1241:71–81. PMID: 22191527.

13. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005; 41:1373–1406. PMID: 16231249.

14. Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila). 2008; 47:211–219. PMID: 18354031.

15. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, et al. New insights into meticillin-resistant staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012; 39:96–104. PMID: 22196394.

16. Food and Drug Administration (FDA). Prescribing information: ALTABAX® (retapamulin ointment), 1%. Silver Spring: FDA;2012.

17. Koning S, van der Wouden JC, Chosidow O, Twynholm M, Singh KP, Scangarella N, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008; 158:1077–1082. PMID: 18341664.

18. Oranje AP, Chosidow O, Sacchidanand S, Todd G, Singh K, Scangarella N, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology. 2007; 215:331–340. PMID: 17911992.

19. Tomayko JF, Li G, Breton JJ, Scangarella-Oman N, Dalessandro M, Martin M. The safety and efficacy of topical retapamulin ointment versus placebo ointment in the treatment of secondarily infected traumatic lesions: a randomized, double-blind superiority study. Adv Skin Wound Care. 2013; 26:113–121. PMID: 23426412.

20. Parish LC, Jorizzo JL, Breton JJ, Hirman JW, Scangarella NE, Shawar RM, et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol. 2006; 55:1003–1013. PMID: 17097398.

21. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010; 74:417–433. PMID: 20805405.

22. Biedenbach DJ, Bouchillon SK, Johnson SA, Hoban DJ, Hackel M. Susceptibility of staphylococcus aureus to topical agents in the United States: a sentinel study. Clin Ther. 2014; 36:953–960. PMID: 24835558.

23. Park SY, Kim SM, Park SD. The prevalence, genotype and antimicrobial susceptibility of high- and low-level mupirocin resistant methicillin-resistant staphylococcus aureus. Ann Dermatol. 2012; 24:32–38. PMID: 22363153.

24. Park SH, Kim JK, Park K. In vitro antimicrobial activities of fusidic acid and retapamulin against mupirocin- and methicillin-resistant staphylococcus aureus. Ann Dermatol. 2015; 27:551–556. PMID: 26512169.

25. Harrington AT, Black JA, Clarridge JE 3rd. In vitro activity of retapamulin and antimicrobial susceptibility patterns in a longitudinal collection of methicillin-resistant staphylococcus aureus isolates from a veterans affairs medical center. Antimicrob Agents Chemother. 2015; 60:1298–1303. PMID: 26666950.

26. Free A, Roth E, Dalessandro M, Hiram J, Scangarella N, Shawar R, et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. Skinmed. 2006; 5:224–232. PMID: 16957433.